{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:23:39Z","timestamp":1780457019952,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA196521"],"award-info":[{"award-number":["P30CA196521"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ygyno.2025.09.010","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:25:00Z","timestamp":1760552700000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement"],"prefix":"10.1016","volume":"202","author":[{"given":"Charles A.","family":"Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira S.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Tarney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3is\u00edn E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.09.010_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1179\/1973947815Y.0000000029","article-title":"Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature","volume":"29","author":"Bielopolski","year":"2017","journal-title":"J. Chemother."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0010","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related Pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner society","volume":"298","author":"Johkoh","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1465-9921-13-39","article-title":"Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches","volume":"13","author":"Matsuno","year":"2012","journal-title":"Respir. Res."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0020","first-page":"7","article-title":"Drug-induced interstitial lung disease: a systematic review","author":"Skeoch","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/annonc\/mdj057","article-title":"Pulmonary toxicity from novel antineoplastic agents","volume":"17","author":"Dimopoulou","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0030","series-title":"Referenced with Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Ovarian Cancer V.3.2024. \u00a9 National Comprehensive Cancer Network, Inc","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0035","series-title":"Referenced with Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Cervical Cancer V.4.2024. \u00a9 National Comprehensive Cancer Network, Inc.","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0040","series-title":"Referenced with Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Uterine Neoplasms V.3.2024. \u00a9 National Comprehensive Cancer Network, Inc","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0045","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0192623318803059","article-title":"A brief introduction to antibody-drug conjugates for Toxicologic pathologists","volume":"46","author":"Mecklenburg","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0060","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","article-title":"Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner society","volume":"8","author":"Hatabu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0065","article-title":"Trastuzumab Deruxtecan\u2013related interstitial lung disease\/pneumonitis: computed tomography imaging patterns to guide diagnosis and management","volume":"7","author":"Nishino","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on Trastuzumab Deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0075","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/OP.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with Trastuzumab Deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast Cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103960","article-title":"Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: a systematic review and meta-analysis","volume":"184","author":"Zhu","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0085","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0095","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.3390\/curroncol30090582","article-title":"Managing the risk of lung toxicity with Trastuzumab Deruxtecan (T-DXd): a Canadian perspective","volume":"30","author":"Henning","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0100","series-title":"ENHERTU","author":"Daiichi","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0105","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of Mirvetuximab Soravtansine in patients with platinum-resistant ovarian Cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0110","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0115","series-title":"ELAHERE","author":"I.","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0130","series-title":"TIVDAK [Prescribing Information]. Bothell, WA","author":"Seagen","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0135","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial Cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0140","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for advanced endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0145","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0150","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0155","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of Pembrolizumab in previously treated advanced cervical Cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0160","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0165","series-title":"Pembrolizumab","author":"Merck","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0170","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0175","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0180","series-title":"JEMPERLI","author":"GSK","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0185","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance Durvalumab with or without Olaparib as first-line treatment for advanced endometrial Cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0190","series-title":"IMFINZI\u00ae (durvalumab) [Prescribing Information]. Wilmington, DE","author":"AstraZeneca","year":"2023"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0195","series-title":"Referenced with Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Gestational Trophoblastic Neoplasia V2..2024. \u00a9 National Comprehensive Cancer Network, Inc","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/mdg020","article-title":"Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours","volume":"14","author":"O\u2019Sullivan","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0205","series-title":"Referenced with Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Vulvar Cancer V.4.2024. \u00a9 National Comprehensive Cancer Network, Inc","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0210","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00001813-200010000-00007","article-title":"Irinotecan-associated pulmonary toxicity","volume":"11","author":"Madarnas","year":"2000","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0272-5231(21)00670-5","article-title":"Pulmonary effects of cytotoxic agents other than bleomycin","volume":"11","author":"Twohig","year":"1990","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0220","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1164\/ajrccm.154.6.8970380","article-title":"Lung toxicity associated with cyclophosphamide use. Two distinct patterns","volume":"154","author":"Malik","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0225","series-title":"LENVIMA [Prescribing Information]. Nutley, NJ. Eisai","year":"2025"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0230","series-title":"Lynparza","author":"AstraZeneca","year":"2023"},{"issue":"5","key":"10.1016\/j.ygyno.2025.09.010_bb0235","article-title":"Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies","volume":"2024","author":"He","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0240","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0245","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0250","doi-asserted-by":"crossref","first-page":"15249","DOI":"10.1007\/s00432-023-05144-9","article-title":"Recent advances and applications of peptide-agent conjugates for targeting tumor cells","volume":"149","author":"Alamdari-Palangi","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137264","article-title":"Biological activity of natural and synthetic peptides as anticancer agents","volume":"25","author":"Bauso","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0260","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1352805","article-title":"Adoptive T cell therapy for solid tumors: current landscape and future challenges","volume":"15","author":"Albarran","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0270","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","article-title":"Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors","volume":"28","author":"Gu","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0275","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2478\/raon-2024-0027","article-title":"Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management","volume":"58","author":"Kovac","year":"2024","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0280","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0285","first-page":"8","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","author":"Maus","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2025.09.010_bb0290","series-title":"Drug-Induced Lung Disease in Rheumatoid Arthritis. UpToDate","author":"Fiona","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.010_bb9040","first-page":"213793","article-title":"Synergistic multimodal adoptive immune cell immunotherapy: Current challenges and future directions","volume":"168","author":"Chang","year":"2024","journal-title":"Biomaterials Advances."},{"key":"10.1016\/j.ygyno.2025.09.010_bb0295","author":"National Cancer Institute: Division of Cancer Treatment & Diagnosis"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:38:32Z","timestamp":1780407512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825010078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":60,"alternative-id":["S0090825825010078"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.09.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}